**NATIONAL CANCER INSTITUTE Autumn Session – LATEST ADVANCEMENTS and DILEMMAS in RECTAL CANCER**

**November 25th 2022**

10:00 – 10:05 Opening speech – director of National Cancer Institute dr. Ernestas Janulionis

10:05 – 10:10 Opening speech – host of the conference assoc. prof. Audrius Dulskas

**Session 1. Moderators prof. Tomas Poskus and assoc. prof. Audrius Dulskas**

10:10 – 10:40prof. **Rodrigo Perez** TNT treatment in rectal cancer – the new gold standard?

10:40 – 11:00 prof. **Narimantas E. Samalavicius** – Local treatment options for early rectal cancer

11:00 – 11:20 prof. **Algimantas Tamelis** – Intrasphincteric resection – to be or not to be

11:20 – 11:40 assoc.prof. **Audrius Dulskas** – Mechanical bowel preparation in low anterior resections

11:40 – 12:00 prof. **Eligijus Poskus** – Early diagnostics of anastomotic leak

12:00 – 12:20 assoc.prof **Saulius Svagzdys** – ELAPE – too much or just enough

12:20 – 12:50prof. **Francesco Bianco** – Pull through - delayed colonial anastomosis without protective stoma

12:50 – 13:20 prof. **Katrine J Emmertsen** – Patient's life following rectal cancer surgery – what is next?

**LUNCH break**

**Session 2. Moderators prof. A.Tamelis ir prof. N.E.Samalavicius**

14:30 – 15:00 prof. **Krzysztof Bujko** – The evolution of rectal cancer treatment from the perspective of a radiotherapist

15:00 – 15:20 prof. **Rasa Janciauskiene** – Novel systemic treatment possibilities in metastatic colorectal cancer

15:20 – 15:40 dr. **Edita Baltruskeviciene** – Immunotherapy for MSI-H colorectal cancer – is it a new standard?

15:40 – 16:00 prof. **Tomas Poskus** – W&W strategy – are we here yet?

16:00 – 16:20 prof. **Rodrigo Perez** – Local regrowths after initial complete clinical response in rectal cancer

16:20 – 16:40 **Ernestas Sileika** – Reirradiation of locally recurrent rectal cancer

16:40 – 17:00 **Michail Klimovskij –** Prevention of hernia – experience with ELAPE patients

17:00 – 17:30 **Joseph Nunoo-Mensah** - High-risk rectal cancer and the interpretation of recent impact trials